Compare Illumina, Inc. (ILMN) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs J M Smucker Co — how do they compare? Illumina, Inc. trades at $191.04 (market cap $27.94B), while J M Smucker Co trades at $114.92 (market cap $11.97B). The key difference: Illumina, Inc. is far larger — about 2.3× J M Smucker Co's market cap, and J M Smucker Co pays a 3.93% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | SJM | |
|---|---|---|
Market Cap | $27.94B | $11.97B |
Sector | Health | Consumer Staples |
52-Week High | $194.33 | $117.05 |
52-Week Low | $91.00 | $89.53 |
Enterprise Value | $29.33B | $19.00B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
J.M. Smucker (SJM) trades at $112.66, up 0.58% today, with a bullish technical signal and strong analyst consensus. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 results are pending. The company maintains a solid dividend, recently increased to $1.12 per share, and benefits from growth in Uncrustables and coffee segments. However, negative net income margin and ROE highlight profitability challenges amid revenue growth to $8.73 billion in 2025.
SJM presents a mixed outlook: valuation metrics like P/E of 22.05 and P/S of 1.32 suggest reasonable pricing, but persistent net losses and high debt pose risks. Analyst price targets average $123.18, implying upside, yet investors must weigh competitive pressures and volatile cash flows against dividend stability and brand strength in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
